The Cold Spring Harbor Laboratory Cancer Center is led by Dr. Bruce Stillman, Dr. Scott Lowe and Dr. Nicholas Tonks. Dr, Stillman has been the Director of the CSHL Cancer Center since 1992. As Director of the Cancer Center, he is responsible for overall direction, strategic planning and raising funds to support the research and Shared Resources. He is assisted in oversight of the Cancer Center by two Deputy Directors, Dr. Scott Lowe and Dr. Nicholas Tonks. Dr. Lowe was appointed Deputy Director for Research of the Cancer Center in 2001. In this position, he is primarily responsible for oversight of the cancer research and programs, strategic planning and recruitment of new members to the Cancer Center. Dr. Nicholas Tonks was appointed Deputy Director for Shared Resources for the Cancer Center in 2007. He supervises all the Shared Resource leaders, provides leadership on funding and is responsible for ongoing periodic Shared Resource review. These three senior leaders are committed to maintaining and improving CSHL as a premier center for cancer research.

Public Health Relevance

The Director and Deputy Directors of the Cold Spring Harbor Laboratory Cancer Center oversee a dynamic and vibrant cancer research program and provide leadership for 32 scientists in three research programs who are committed to understanding the underlying mechanisms of cancer as a means to developing strategies for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA045508-24
Application #
8340277
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-08-17
Project End
2016-07-31
Budget Start
2011-08-17
Budget End
2012-07-31
Support Year
24
Fiscal Year
2011
Total Cost
$241,027
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8
Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel et al. (2018) Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23:62-70
Hwang, Dong-Woo; Jaganathan, Anbalagan; Shrestha, Padmina et al. (2018) Chromatin-mediated translational control is essential for neural cell fate specification. Life Sci Alliance 1:e201700016
Goncalves, Marcus D; Hwang, Seo-Kyoung; Pauli, Chantal et al. (2018) Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci U S A 115:E743-E752
Biffi, Giulia; Oni, Tobiloba E; Spielman, Benjamin et al. (2018) IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov :
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Aznarez, Isabel; Nomakuchi, Tomoki T; Tetenbaum-Novatt, Jaclyn et al. (2018) Mechanism of Nonsense-Mediated mRNA Decay Stimulation by Splicing Factor SRSF1. Cell Rep 23:2186-2198
Fang, Han; Huang, Yi-Fei; Radhakrishnan, Aditya et al. (2018) Scikit-ribo Enables Accurate Estimation and Robust Modeling of Translation Dynamics at Codon Resolution. Cell Syst 6:180-191.e4
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :

Showing the most recent 10 out of 380 publications